目的:分析醋酸曲普瑞林在治疗女童中枢性性早熟中的临床疗效与安全性.方法:以我院收治的64例中枢性性早熟女童(6～7岁)作为观察组,并以于我院进行生殖健康体检(两次体检时间间隔约为1年)的74例健康女童(6～7岁)作为对照组.观察组患童采用醋酸曲普瑞林治疗,1年为1个疗程.对比分析两组第二性征指标、生长发育指标以及性激素水平变化情况,同时分析观察组治疗期间治疗疗效及不良反应的发生情况.结果:观察组患童经1个疗程醋酸曲普瑞林治疗后的生长发育指标、第二性征指标以及性激素水平与观察组患童治疗前比较差异具有统计学意义(P＜0.05),同时,观察组患童经1个疗程醋酸曲普瑞林治疗后的第二性征指标、性激素水平以及生长发育部分指标与对照组女童1年后体检的对应指标比较差异无统计学意义(P＞0.05),但观察组患童经1个疗程醋酸曲普瑞林治疗后预测成年终身高与对照组女童1年后体检的预测成年终身高比较差异具有统计学意义(P＜0.05);观察组总治疗有效率为90.63％,治疗期间基本无不良反应发生.结论:醋酸曲普瑞林在治疗女性中枢性性早熟中疗效确切,且具有较高的安全性,醋酸曲普瑞林可有效降低中枢性性早熟患童性激素水平,防止患童第二性征和生长发育的提前,且对患童预测成年终身高的影响并不显著,醋酸曲普瑞林是治疗女性中枢性性早熟的有效药物,值得临床推广.%Objectives:To analyze the curative effect and security of triptorelin acetate in the treatment of female patients with central precocious puberty.Methods:64 patients with central precocious puberty (6 ～ 7 years old) in our hospital were selected as observation group,and 74 healthy children (6 ～ 7 years old) in our reproductive health for physical examination (interval of about 1 year) were selected as control group.Observation group received triptorelin acetate for 1 year as a course of treatment.The secondary sex characteristic,growth index and the change in sex hormone levels between the two groups were compared,and the curative effect and adverse reaction in observation group was also observed.Results:After a course of treatment,differences in the secondary sex characteristic,growth index and the change in sex hormone levels between the two groups were statistically significant (P ＜ 0.05).Difference in the secondary sex characteristic,growth index and sex hormone levels between the two groups in the physical examination a year later had no statistical significance (P ＞ 0.05),but difference in the predicted adult height between the two groups in the physical examination a year later had no statistical significance (P ＜ 0.05).The total effective rate of the observation group was 90.63％,without adverse reactions during treatment.Conclusion:Triptorelin acetate is safe and effective in treating female patients with central precocious puberty,which can prevent the premature development of sex characteristics with little impact on the predicted adult height of patients,thusly worth clinical promotion.
展开▼
